![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
T Kronbach, D Mathys, M Umeno, FJ Gonzalez and UA Meyer
Department of Pharmacology, Biocenter of the University, Basel/Switzerland.
The metabolism of midazolam and triazolam to their 1'-hydroxy and 4- hydroxy metabolites was studied in microsomes of 15 human livers. The formation of both metabolites was inhibited by more than 90% by an antiserum directed against a pregnenolone 16 alpha-carbonitrile- inducible cytochrome P450 (P450PCN1) of rat liver. Moreover, midazolam hydroxylase activity was immunoprecipitated from solubilized human microsomes with polyclonal antibodies against rat P450PCN1 and the closely related human isozyme P450NF. A close correlation was observed between the amount of protein detected in immunoblots with these antibodies and the midazolam or triazolam hydrxylase activity. The formation of both metabolites of midazolam was inhibited by triacetyloleandomycin, a known inhibitor of cytochromes P450 of the IIIA family. Direct evidence that P450IIIA4 catalyzes the metabolism of midazolam was provided through the use of cDNA-directed expression. Monkey COS cells transfected with human P450PCN1 cDNA were able to catalyze both the 1'- and the 4-hydroxylation of midazolam. We conclude that the metabolism of midazolam and triazolam in human liver is predominantly mediated by cytochrome P450IIIA4. Two of 15 human livers expressed a second immunoreactive microsomal protein of higher apparent Mr and were more active in midazolam 1'-hydroxylation. Our data also provide evidence that the marked interindividual variation in the response to these widely used benzodiazepine drugs is due to variable hepatic metabolism.
This article has been cited by other articles:
|
|
 |
|
  S. Klieber, S. Hugla, R. Ngo, C. Arabeyre-Fabre, V. Meunier, F. Sadoun, O. Fedeli, M. Rival, M. Bourrie, F. Guillou, et al. Contribution of the N-Glucuronidation Pathway to the Overall in Vitro Metabolic Clearance of Midazolam in Humans Drug Metab. Dispos., May 1, 2008; 36(5): 851 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. B. van Waterschoot, A. E. van Herwaarden, J. S. Lagas, R. W. Sparidans, E. Wagenaar, C. M. M. van der Kruijssen, J. A. Goldstein, D. C. Zeldin, J. H. Beijnen, and A. H. Schinkel Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C Enzymes Mol. Pharmacol., March 1, 2008; 73(3): 1029 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Abass, P. Reponen, M. Turpeinen, J. Jalonen, and O. Pelkonen Characterization of Diuron N-Demethylation by Mammalian Hepatic Microsomes and cDNA-Expressed Human Cytochrome P450 Enzymes Drug Metab. Dispos., September 1, 2007; 35(9): 1634 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kohalmy, V. Tamasi, L. Kobori, E. Sarvary, J.-M. Pascussi, P. Porrogi, D. Rozman, R. A. Prough, U. A. Meyer, and K. Monostory Dehydroepiandrosterone Induces Human CYP2B6 through the Constitutive Androstane Receptor Drug Metab. Dispos., September 1, 2007; 35(9): 1495 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Ma, S. L. Polsky-Fisher, S. Vickers, D. Cui, and A. D. Rodrigues Cytochrome P450 3A-Dependent Metabolism of a Potent and Selective {gamma}-Aminobutyric AcidA{alpha}2/3 Receptor Agonist in Vitro: Involvement of Cytochrome P450 3A5 Displaying Biphasic Kinetics Drug Metab. Dispos., August 1, 2007; 35(8): 1301 - 1307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Farkas, L. E. Oleson, Y. Zhao, J. S. Harmatz, M. A. Zinny, M. H. Court, and D. J. Greenblatt Pomegranate Juice Does Not Impair Clearance of Oral or Intravenous Midazolam, a Probe for Cytochrome P450-3A Activity: Comparison With Grapefruit Juice J. Clin. Pharmacol., March 1, 2007; 47(3): 286 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zhang, T. M. C. Tan, and L.-Y. Lim Impact of Curcumin-Induced Changes in P-Glycoprotein and CYP3A Expression on the Pharmacokinetics of Peroral Celiprolol and Midazolam in Rats Drug Metab. Dispos., January 1, 2007; 35(1): 110 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zhou, E.-J. Poulton, F. Grun, T. K. Bammler, B. Blumberg, K. E. Thummel, and D. L. Eaton The Dietary Isothiocyanate Sulforaphane Is an Antagonist of the Human Steroid and Xenobiotic Nuclear Receptor Mol. Pharmacol., January 1, 2007; 71(1): 220 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Li, M. O. Karlsson, J. Brahmer, A. Spitz, M. Zhao, M. Hidalgo, and S. D. Baker CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors J Natl Cancer Inst, December 6, 2006; 98(23): 1714 - 1723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Uchida, H. Yamada, X. D. Li, S. Maruyama, Y. Ohmori, T. Oki, H. Watanabe, K. Umegaki, K. Ohashi, and S. Yamada Effects of ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J. Clin. Pharmacol., November 1, 2006; 46(11): 1290 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Carr, R. Norcross, Y. Fang, P. Lu, A. D. Rodrigues, M. Shou, T. Rushmore, and C. Booth-Genthe Characterization of the Rhesus Monkey CYP3A64 Enzyme: Species Comparisons of CYP3A Substrate Specificity and Kinetics Using Baculovirus-Expressed Recombinant Enzymes Drug Metab. Dispos., October 1, 2006; 34(10): 1703 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Day, C. G. Plopper, and M. V. Fanucchi Age-specific pulmonary cytochrome P-450 3A1 expression in postnatal and adult rats Am J Physiol Lung Cell Mol Physiol, July 1, 2006; 291(1): L75 - L83. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zollinger, F. Waldmeier, S. Hartmann, G. Zenke, A. G. Zimmerlin, U. Glaenzel, J.-P. Baldeck, A. Schweitzer, S. Berthier, T. Moenius, et al. PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO Drug Metab. Dispos., May 1, 2006; 34(5): 765 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tachibana, Y. Fujimaki, H. Yokoyama, O. Okazaki, and K.-i. Sudo IN VITRO METABOLISM OF THE CALMODULIN ANTAGONIST DY-9760e (3-[2-[4-(3-CHLORO-2-METHYLPHENYL)-1-PIPERAZINYL]ETHYL]-5,6-DIMETHOXY-1-(4-IMIDAZOLYLMETHYL)-1H-INDAZOLE DIHYDROCHLORIDE 3.5 HYDRATE) BY HUMAN LIVER MICROSOMES: INVOLVEMENT OF CYTOCHROMES P450 IN ATYPICAL KINETICS AND POTENTIAL DRUG INTERACTIONS Drug Metab. Dispos., November 1, 2005; 33(11): 1628 - 1636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Klees, P. Sheffels, O. Dale, and E. D. Kharasch METABOLISM OF ALFENTANIL BY CYTOCHROME P4503A (CYP3A) ENZYMES Drug Metab. Dispos., March 1, 2005; 33(3): 303 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Huang, Y. S. Lin, D. J. McConn II, J. C. Calamia, R. A. Totah, N. Isoherranen, M. Glodowski, and K. E. Thummel EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM Drug Metab. Dispos., December 1, 2004; 32(12): 1434 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Jones and J. B. Houston SUBSTRATE DEPLETION APPROACH FOR DETERMINING IN VITRO METABOLIC CLEARANCE: TIME DEPENDENCIES IN HEPATOCYTE AND MICROSOMAL INCUBATIONS Drug Metab. Dispos., September 1, 2004; 32(9): 973 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J Hewitt and D. Utesch Cryopreserved rat, dog and monkey hepatocytes: measurement of drug metabolizing enzymes in suspensions and cultures Human and Experimental Toxicology, June 1, 2004; 23(6): 307 - 316. [Abstract] [PDF]
|
|
|
|
|
|
N. E. Martin, S. R. Howell, L. L. Martin, I. Cirillo, and J. S. Barrett No Clinically Relevant CYP3A Induction with the Dual Angiotensin-Converting Enzyme/Neutral Endopeptidase Inhibitor, M100240 J. Clin. Pharmacol., April 1, 2004; 44(4): 379 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Shen, J. F. Fitzloff, and C. S. Cook DIFFERENTIAL ENANTIOSELECTIVITY AND PRODUCT-DEPENDENT ACTIVATION AND INHIBITION IN METABOLISM OF VERAPAMIL BY HUMAN CYP3AS Drug Metab. Dispos., February 1, 2004; 32(2): 186 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Patki, L. L. von Moltke, and D. J. Greenblatt IN VITRO METABOLISM OF MIDAZOLAM, TRIAZOLAM, NIFEDIPINE, AND TESTOSTERONE BY HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROMES P450: ROLE OF CYP3A4 AND CYP3A5 Drug Metab. Dispos., July 1, 2003; 31(7): 938 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Weaver, K. S. Graham, I. G. Beattie, and R. J. Riley CYTOCHROME P450 INHIBITION USING RECOMBINANT PROTEINS AND MASS SPECTROMETRY/MULTIPLE REACTION MONITORING TECHNOLOGY IN A CASSETTE INCUBATION Drug Metab. Dispos., July 1, 2003; 31(7): 955 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Granvil, A.-M. Yu, G. Elizondo, T. E. Akiyama, C. Cheung, L. Feigenbaum, K. W. Krausz, and F. J. Gonzalez Expression of the Human CYP3A4 Gene in the Small Intestine of Transgenic Mice: In Vitro Metabolism and Pharmacokinetics of Midazolam Drug Metab. Dispos., May 1, 2003; 31(5): 548 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Y. H. Lu, R. W. Wang, and J. H. Lin Cytochrome P450 In Vitro Reaction Phenotyping: A Re-evaluation of Approaches Used for P450 Isoform Identification Drug Metab. Dispos., April 1, 2003; 31(4): 345 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Yuan, S. Madani, X.-X. Wei, K. Reynolds, and S.-M. Huang Evaluation of Cytochrome P450 Probe Substrates Commonly Used by the Pharmaceutical Industry to Study in Vitro Drug Interactions Drug Metab. Dispos., December 1, 2002; 30(12): 1311 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kotegawa, B. E. Laurijssens, L. L. von Moltke, M. M. Cotreau, M. D. Perloff, K. Venkatakrishnan, J. S. Warrington, B. W. Granda, J. S. Harmatz, and D. J. Greenblatt In Vitro, Pharmacokinetic, and Pharmacodynamic Interactions of Ketoconazole and Midazolam in the Rat J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1228 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ibrahim, A. Karim, J. Feldman, and E. Kharasch The Influence of Parecoxib, a Parenteral Cyclooxygenase-2 Specific Inhibitor, on the Pharmacokinetics and Clinical Effects of Midazolam Anesth. Analg., September 1, 2002; 95(3): 667 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Nagashima, E Tanaka, S Inomata, and S Misawa A study of the in vitro clinical interaction between lidocaine and premedications using rat liver microsomes Human and Experimental Toxicology, August 1, 2002; 21(8): 453 - 456. [Abstract] [PDF]
|
|
|
|
|
|
K. K. Khan, Y. Q. He, T. L. Domanski, and J. R. Halpert Midazolam Oxidation by Cytochrome P450 3A4 and Active-Site Mutants: an Evaluation of Multiple Binding Sites and of the Metabolic Pathway That Leads to Enzyme Inactivation Mol. Pharmacol., March 1, 2002; 61(3): 495 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Uckun, J. Thoen, H. Chen, E. Sudbeck, C. Mao, R. Malaviya, X.-P. Liu, and C.-L. Chen CYP1A-Mediated Metabolism of the Janus Kinase-3 Inhibitor 4-(4'-Hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: Structural Basis for Inactivation by Regioselective O-Demethylation Drug Metab. Dispos., January 1, 2002; 30(1): 74 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. C. 't Hoen, M. K. Bijsterbosch, T. J. C. van Berkel, N. P. E. Vermeulen, and J. N. M. Commandeur Midazolam Is a Phenobarbital-Like Cytochrome P450 Inducer in Rats J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 921 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Stresser, A. P. Blanchard, S. D. Turner, J. C. L. Erve, A. A. Dandeneau, V. P. Miller, and C. L. Crespi Substrate-Dependent Modulation of CYP3A4 Catalytic Activity: Analysis of 27 Test Compounds with Four Fluorometric Substrates Drug Metab. Dispos., April 13, 2001; 28(12): 1440 - 1448. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Hamaoka, Y. Oda, I. Hase, and A. Asada Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies Br. J. Anaesth., April 1, 2001; 86(4): 540 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Schrag and L. C. Wienkers Triazolam Substrate Inhibition: Evidence of Competition for Heme-Bound Reactive Oxygen Within the CYP3A4 Active Site Drug Metab. Dispos., January 1, 2001; 29(1): 70 - 75. [Abstract] [Full Text]
|
|
|
|
|
|
T. L. Domanski, Y.-A. He, G. R. Harlow, and J. R. Halpert Dual Role of Human Cytochrome P450 3A4 Residue Phe-304 in Substrate Specificity and Cooperativity J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 585 - 591. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. A. Bernard and E. Bruera Drug Interactions in Palliative Care J. Clin. Oncol., April 1, 2000; 18(8): 1780 - 1799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Houston and K. E. Kenworthy In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model Drug Metab. Dispos., March 1, 2000; 28(3): 246 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Wang, D. J. Newton, N. Liu, W. M. Atkins, and A. Y. H. Lu Human Cytochrome P-450 3A4: In Vitro Drug-Drug Interaction Patterns Are Substrate-Dependent Drug Metab. Dispos., March 1, 2000; 28(3): 360 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Perloff, L. L. von Moltke, M. H. Court, T. Kotegawa, R. I. Shader, and D. J. Greenblatt Midazolam and Triazolam Biotransformation in Mouse and Human Liver Microsomes: Relative Contribution of CYP3A and CYP2C Isoforms J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 618 - 628. [Abstract] [Full Text]
|
|
|
|
|
|
V. P. Hosagrahara, L. K. Hansen, and R. P. Remmel Induction of the Metabolism of Midazolam by Rifampin in Cultured Porcine Hepatocytes: Preliminary Evidence for CYP3A Isoforms in Pigs Drug Metab. Dispos., December 1, 1999; 27(12): 1512 - 1518. [Abstract] [Full Text]
|
|
|
|
|
|
A. Suzuki, I. Iida, F. Tanaka, M. Akimoto, K. Fukushima, M. Tani, T. Ishizaki, and K. Chiba Identification of Human Cytochrome P-450 Isoforms Involved in Metabolism of R(+)- and S(-)-Gallopamil: Utility of In Vitro Disappearance Rate Drug Metab. Dispos., November 1, 1999; 27(11): 1254 - 1259. [Abstract] [Full Text]
|
|
|
|
|
|
S. Ekins, G. Bravi, J. H. Wikel, and S. A. Wrighton Three-Dimensional-Quantitative Structure Activity Relationship Analysis of Cytochrome P-450 3A4 Substrates J. Pharmacol. Exp. Ther., October 1, 1999; 291(1): 424 - 433. [Abstract] [Full Text]
|
|
|
|
|
|
H. Yamazaki, M. Nakajima, M. Nakamura, S. Asahi, N. Shimada, E. M. J. Gillam, F. P. Guengerich, T. Shimada, and T. Yokoi Enhancement of Cytochrome P-450 3A4 Catalytic Activities by Cytochrome b5 in Bacterial Membranes Drug Metab. Dispos., September 1, 1999; 27(9): 999 - 1004. [Abstract] [Full Text]
|
|
|
|
|
|
K. Kobayashi, T. Ishizuka, N. Shimada, Y. Yoshimura, K. Kamijima, and K. Chiba Short Communication: Sertraline N-Demethylation Is Catalyzed by Multiple Isoforms of Human Cytochrome P-450 In Vitro Drug Metab. Dispos., July 1, 1999; 27(7): 763 - 766. [Abstract] [Full Text]
|
|
|
|
|
|
X.-J. Zhao, E. Koyama, and T. Ishizaki An In Vitro Study on the Metabolism and Possible Drug Interactions of Rokitamycin, a Macrolide Antibiotic, Using Human Liver Microsomes Drug Metab. Dispos., July 1, 1999; 27(7): 776 - 785. [Abstract] [Full Text]
|
|
|
|
|
|
S. Ekins, G. Bravi, S. Binkley, J. S. Gillespie, B. J. Ring, J. H. Wikel, and S. A Wrighton Three- and Four-Dimensional Quantitative Structure Activity Relationship Analyses of Cytochrome P-450 3A4 Inhibitors J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 429 - 438. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Fisher, S. A. Wrighton, J. C. Calamia, D. D. Shen, K. L. Kunze, and K. E. Thummel Midazolam Metabolism by Modified Caco-2 Monolayers: Effects of Extracellular Protein Binding J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 1143 - 1150. [Abstract] [Full Text]
|
|
|
|
|
|
S. D. Hall, K. E. Thummel, P. B. Watkins, K. S. Lown, L. Z. Benet, M. F. Paine, R. R. Mayo, D. K. Turgeon, D. G. Bailey, R. J. Fontana, et al. Molecular and Physical Mechanisms of First-Pass Extraction Drug Metab. Dispos., February 1, 1999; 27(2): 161 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Pellock Topical Review: Use of Midazolam for Refractory Status Epilepticus in Pediatric Patients J Child Neurol, December 1, 1998; 13(12): 581 - 587. [Abstract] [PDF]
|
|
|
|
|
|
R. L. Voorman, S. M. Maio, N. A. Payne, Z. Zhao, K. A. Koeplinger, and X. Wang Microsomal Metabolism of Delavirdine: Evidence for Mechanism-Based Inactivation of Human Cytochrome P450 3A J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 381 - 388. [Abstract] [Full Text]
|
|
|
|
|
|
S. Ekins, M. Vandenbranden, B. J. Ring, J. S. Gillespie, T. J. Yang, H. V. Gelboin, and S. A. Wrighton Further Characterization of the Expression in Liver and Catalytic Activity of CYP2B6 J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1253 - 1259. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Liddle, B. J. Goodwin, J. George, M. Tapner, and G. C. Farrell Separate and Interactive Regulation of Cytochrome P450 3A4 by Triiodothyronine, Dexamethasone, and Growth Hormone in Cultured Hepatocytes J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2411 - 2416. [Abstract] [Full Text]
|
|
|
|
|
|
T. Hashizume, M. Mise, Y. Terauchi, L. O, T. Fujii, H. Miyazaki, and T. Inaba N-Dealkylation and Hydroxylation of Ebastine by Human Liver Cytochrome P450 Drug Metab. Dispos., June 1, 1998; 26(6): 566 - 571. [Abstract] [Full Text]
|
|
|
|
|
|
A. J. Draper, A. Madan, K. Smith, and A. Parkinson Development of a Non-High Pressure Liquid Chromatography Assay to Determine Testosterone Hydroxylase (CYP3A) Activity in Human Liver Microsomes Drug Metab. Dispos., April 1, 1998; 26(4): 299 - 304. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Fahey, G. A. Pritchard, L. L. v. Moltke, J. S. Pratt, J. M. Grassi, R. I. Shader, and D. J. Greenblatt Effects of Ketoconazole on Triazolam Pharmacokinetics, Pharmacodynamics and Benzodiazepine Receptor Binding in Mice J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 271 - 276. [Abstract] [Full Text]
|
|
|
|
|
|
C. Wandel, R. H. Böcker, H. Böhrer, J. X. deVries, W. Hofmann, K. Walter, B. Kleingeist, S. Neff, R. Ding, I. Walter-Sack, et al. Relationship between Hepatic Cytochrome P450 3A Content and Activity and the Disposition of Midazolam Administered Orally Drug Metab. Dispos., February 1, 1998; 26(2): 110 - 114. [Abstract] [Full Text]
|
|
|
|
|
|
M. F. Paine, M. Khalighi, J. M. Fisher, D. D. Shen, K. L. Kunze, C. L. Marsh, J. D. Perkins, and K. E. Thummel Characterization of Interintestinal and Intraintestinal Variations in Human CYP3A-Dependent Metabolism J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1552 - 1562. [Abstract] [Full Text]
|
|
|
|
|
|
D. Sutton, A. M. Butler, L. Nadin, and M. Murray Role of CYP3A4 in Human Hepatic Diltiazem N-Demethylation: Inhibition of CYP3A4 Activity by Oxidized Diltiazem Metabolites J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 294 - 300. [Abstract] [Full Text]
|
|
|
|
|
|
P. Schmiedlin-Ren, K. E. Thummel, J. M. Fisher, M. F. Paine, K. S. Lown, and P. B. Watkins Expression of Enzymatically Active CYP3A4 by Caco-2 Cells Grown on Extracellular Matrix-Coated Permeable Supports in the Presence of 1alpha ,25-Dihydroxyvitamin D3 Mol. Pharmacol., May 1, 1997; 51(5): 741 - 754. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. R. Harlow and J. R. Halpert Alanine-scanning Mutagenesis of a Putative Substrate Recognition Site in Human Cytochrome P450 3A4. ROLE OF RESIDUES 210AND 211IN FLAVONOID ACTIVATION AND SUBSTRATE SPECIFICITY J. Biol. Chem., February 28, 1997; 272(9): 5396 - 5402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kobayashi, K. Chiba, T. Yagi, N. Shimada, T. Taniguchi, T. Horie, M. Tani, T. Yamamoto, T. Ishizaki, and Y. Kuroiwa Identification of Cytochrome P450 Isoforms Involved in Citalopram N-Demethylation by Human Liver Microsomes J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 927 - 933. [Abstract] [Full Text]
|
